Literature DB >> 21816254

Non-invasive anterior segment and posterior segment optical coherence tomography and phenotypic characterization of aniridia.

Kevin Gregory-Evans1, Richard Cheong-Leen, Sheena M George, Judy Xie, Mariya Moosajee, Patricio Colapinto, Cheryl Y Gregory-Evans.   

Abstract

OBJECTIVE: To determine the value of optical coherence tomography (OCT) as a diagnostic tool in the critical evaluation of phenotypic variability seen in an aniridia family with a novel PAX6 mutation.
DESIGN: Genetic and observational family study. PARTICIPANTS: Three-generation family segregating autosomal dominant aniridia.
METHODS: Ophthalmic examination included best-corrected visual acuity, slit-lamp biomicroscopy, direct and indirect ophthalmoscopy, tonometry, and OCT. PAX6 gene mutation analysis was carried out by direct sequencing of gene-specific PCR products and protein analysis by Western blot.
RESULTS: Intrafamilial variable expressivity was seen between 4 affected family members. Phenotype differences between twin children suggested that this was due to modifier gene effects rather than environment. Anterior segment OCT demonstrated a range of iridocorneal angle abnormalities and corneal thickening in only 3, but ciliary body hypoplasia in all 4 affected patients. Posterior segment OCT demonstrated dome-shaped, hypoplastic macular profiles in the 2 affected children. Novel outer retinal changes were also seen, suggestive of a phototoxic retinopathy not previously recognized in aniridia. Ocular disease segregated with a novel PAX6 Q178X nonsense mutation with Western blot analysis suggesting that this led to haploinsufficiency of PAX6 protein.
CONCLUSIONS: Non-contact OCT imaging allowed for a more detailed assessment of anterior and posterior segment disease in children and adults with aniridia plus nystagmus. This led to the identification of novel features and highlights a practical, non-contact strategy well suited to genotype/phenotype studies and the longitudinal management of aniridic glaucoma in children.
Copyright © 2011 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21816254     DOI: 10.1016/j.jcjo.2011.06.011

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  8 in total

1.  The Cone Photoreceptor Mosaic in Aniridia: Within-Family Phenotype-Genotype Discordance.

Authors:  Hilde R Pedersen; Maureen Neitz; Stuart J Gilson; Erlend C S Landsend; Øygunn Aas Utheim; Tor Paaske Utheim; Rigmor C Baraas
Journal:  Ophthalmol Retina       Date:  2019-02-05

Review 2.  Genetic modifiers as relevant biological variables of eye disorders.

Authors:  Kacie J Meyer; Michael G Anderson
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

3.  [Aniridia syndrome: clinical findings, problematic courses and suggestions for optimization of care ("aniridia guide")].

Authors:  B Käsmann-Kellner; B Seitz
Journal:  Ophthalmologe       Date:  2014-12       Impact factor: 1.059

4.  Ultrasound biomicroscopic imaging demonstrate thinner ciliary body thickness in eyes with angle closure.

Authors:  Shi-Yan Chen; Na He; Yu-Jie Yan; Xiang Fan; Ling-Ling Wu
Journal:  Int J Ophthalmol       Date:  2022-09-18       Impact factor: 1.645

5.  A splice site mutation in the PAX6 gene which induces exon skipping causes autosomal dominant inherited aniridia.

Authors:  Nicole Weisschuh; Bernd Wissinger; Eugen Gramer
Journal:  Mol Vis       Date:  2012-03-29       Impact factor: 2.367

6.  Color Vision in Aniridia.

Authors:  Hilde R Pedersen; Lene A Hagen; Erlend C S Landsend; Stuart J Gilson; Øygunn A Utheim; Tor P Utheim; Maureen Neitz; Rigmor C Baraas
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

7.  Morphometric analysis of the lens in human aniridia and mouse Small eye.

Authors:  Anna Voskresenskaya; Nadezhda Pozdeyeva; Yevgeniy Batkov; Tatyana Vasilyeva; Andrey Marakhonov; Richard A West; Jeffrey L Caplan; Ales Cvekl; Yan Wang; Melinda K Duncan
Journal:  Exp Eye Res       Date:  2020-11-26       Impact factor: 3.467

8.  Epistasis between Pax6Sey and genetic background reinforces the value of defined hybrid mouse models for therapeutic trials.

Authors:  Jack W Hickmott; Uvini Gunawardane; Kimberly Jensen; Andrea J Korecki; Elizabeth M Simpson
Journal:  Gene Ther       Date:  2018-09-26       Impact factor: 5.250

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.